EMG
SNDX icon

ETF Managers Group’s Syndax Pharmaceuticals SNDX Stock Holding History

ETF Managers Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,111
Closed -$597K – 682
2020
Q4 		$597K Buy
+26,111
New +$542K 0.01% 304

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ETF Managers Group's SNDX Position: Q1 2021 in Review

ETF Managers Group sold out of Syndax Pharmaceuticals (SNDX) in Q1 2021, closing a stake of 26,111 shares — an estimated $597K sold.

ETF Managers Group first reported a position in SNDX in Q4 2020 and held it in 1 quarter. The position peaked at $597K in Q4 2020. 130 funds tracked by Wall St. Rank hold SNDX as of Q1 2021.

  • ETF Managers Group reported no remaining Syndax Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • ETF Managers Group sold 26,111 Syndax Pharmaceuticals shares in Q1 2021, an estimated $597K.
  • ETF Managers Group first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • ETF Managers Group's Syndax Pharmaceuticals position peaked at $597K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2021.

Based on ETF Managers Group's 13F filing for Q1 2021, filed 17 May 2021.